Navigation Links
Alexandria Real Estate Equities, Inc. Features Green Buildings and Sustainable Operations Initiatives and Tour at 2008 BIO
Date:6/16/2008

PASADENA, Calif., June 16 /PRNewswire/ -- Alexandria Real Estate Equities, Inc. (NYSE: ARE) today will shuttle more than 100 life science executives from around the world on a tour of Green and LEED certified buildings and environmentally sustainable operations in the San Diego life science cluster market. This unique BIO Bus Tour is being held in conjunction with the Biotechnology Industry Organization's International 2008 Convention taking place in San Diego, California.

Alexandria has a dominant market position in its San Diego life science cluster market. It currently owns and operates approximately 2.2 million square feet of office/laboratory space in that market, including approximately 440,000 square feet of embedded future ground up development. San Diego is home to leading pharmaceutical, biotechnology, life science product and service companies, as well as renowned scientific research institutions. Alexandria has strongly supported and assisted the growth of the life science industry in San Diego. Alexandria includes amongst its prestigious client tenants in San Diego: Amylin Pharmaceuticals, Inc., The Scripps Research Institute, Syngenta AG, Laboratory Corporation of America, Senomyx, Inc., Biogen Idec, Arena Pharmaceuticals, Inc., Smith & Nephew plc, Ambrx, Inc., Genzyme Corporation, Forward Ventures and Becton, Dickinson and Company.

The tour will be conducted at the premises of several Alexandria client tenants: the amenities building of Amylin Pharmaceuticals, Inc. located at 4575 Eastgate Mall, which has received LEED Certification, and The Burnham Institute for Medical Research, located at 3010 Science Park Road for which LEED status is being pursued. The tour will also include visits to University of California San Diego, the Salk Institute for Biological Studies, The Scripps Research Institute, Genomics Institute of the Novartis Research Foundation and the headquarters of Biogen Idec. The facilities featured on the tour will highlight conservation efforts at various life science institutions and will also demonstrate how operations at office/laboratory buildings have been improved in order to become energy efficient and environmentally sustainable.

"As the pioneer at the vanguard of the sustainability initiative in our office/ laboratory niche, Alexandria continues to build on its world class expertise and experience in its life science cluster strategy, leading the way toward implementing sustainable materials and operational performance with green technologies in the laboratory environment," said Joel S. Marcus, Chief Executive Officer of Alexandria. "We are proud to have been the first company in California to have a Core and Shell laboratory project to be LEED Silver certified and we continue to innovate with the design and construction of state-of-the-art office/laboratory spaces that meet the needs of the industry. There is also great interest in net zero energy consumption which Alexandria is heavily focused on as well."

Alexandria's high performance green buildings are equipped with high efficiency chillers and boilers, non-chemical water treatment systems and recycled materials. The buildings utilize day lighting, spectrally selective glazing, motion sensors and dimming controls. These efficiencies reduce HVAC (heating, ventilating and air conditioning) electricity consumption and decrease water use.

Mr. Marcus continued, "We have proven that life science entities do not have to sacrifice functionality in order to be environmentally efficient. In fact, our leading green initiatives help lower tenant costs and operating expenses while continuing to provide entities with a state-of-the-art work environment that fosters continued translation of leading edge science and breakthrough products which contribute significantly to better human health."

About LEED (Leadership in Energy and Environmental Design)

LEED is the nationally accepted benchmark for the design, construction and operation of high performance green buildings. LEED promotes a whole-building approach to sustainability by recognizing performance in five key areas of human and environmental health: sustainable site development, water savings, energy efficiency, materials selection and indoor environmental quality.

Alexandria Real Estate Equities, Inc., Landlord of Choice to the Life Science Industry(R), is the largest owner and preeminent first-in-class international real estate investment trust focused principally on science- driven cluster formation through the ownership, operation, management, redevelopment, selective development and acquisition of properties containing technical environments, including office/laboratory space. Alexandria is the leading provider of high-quality environmentally sustainable real estate, technical infrastructure, services and capital to the broad and diverse life science industry. Client tenants include institutional (universities and independent not-for-profit institutions), pharmaceutical, biotechnology, medical device, product, service, and translational entities, as well as government agencies. Alexandria's operating platform is based on the principle of "clustering," with assets and operations located in key life science markets. Our asset base approximates 13.3 million rentable square feet consisting of 159 properties approximating 11.7 million rentable square feet (including spaces undergoing active redevelopment) and properties undergoing ground-up development approximating 1.6 million rentable square feet. In addition, our asset base will enable us to grow to approximately 22.3 million square feet through future ground-up development approximating 9.0 million square feet of office/laboratory space.

This press release contains forward-looking statements within the meaning of the federal securities laws. Actual results may differ materially from those projected in the forward-looking statements. Additional information concerning factors that could cause actual results to differ materially from those in the forward-looking statements is contained in our Annual Report on Form 10-K and our other periodic reports filed with the Securities and Exchange Commission.


'/>"/>
SOURCE Alexandria Real Estate Equities, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Alexandria Real Estate Equities, Inc. Reports Third Quarter 2007 Results
2. Environmental Power Holds Ground Breaking Ceremony for Renewable Natural Gas Facility at Rio Leche Estates
3. Rosetta Genomics Announces Expansion of its MicroRNA Intellectual Property Estate
4. Unigene Restates Policy on Analyst Reports
5. Angiotech announces filing of audited financial results for the year ended December 31, 2007 and restatement of results for the year ended December 31, 2006
6. Symmetry Medical Discloses Accounting Issues at Sheffield, UK Operating Unit and Possible Restatement
7. Coherent Announces Restatement Related to Stock-Based Compensation
8. Xceed Molecular Features Ziplex(R) Automated Gene-Expression System at the Biomarker World Congress, Booth 16
9. Vermillions Roundtable Teleconference Highlights Peripheral Artery Disease Diagnostic Program; Features Commentary from Vascular Medicine Expert
10. National Public Radio (NPR) Features Broadcast Articles on NanoLogix Hydrogen Bioreactor Operation at Welchs Foods
11. Challenge Spreadable Butter Now Features Marteks lifesDHA(TM)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/16/2017)... ... ... EIT Digital has launched work to develop a new Smart IOT ... to get under way for the framework, which is designed to reduce the use ... to be transferred eventually to other industries that also require efficient IoT and management ...
(Date:2/16/2017)... , Feb. 16, 2017  MDNA Life ... the development of liquid biopsy tests based on ... into an exclusive license agreement with its first ... proprietary liquid biopsy test for prostate cancer, the ... Korea . This is the first overseas ...
(Date:2/16/2017)... Feb. 16, 2017   Biostage, Inc. (Nasdaq: ... biotechnology company developing bioengineered organ implants to treat cancers ... trachea, announced today the closing on February 15, 2017 ... of common stock and warrants to purchase 20,000,000 shares ... million. The offering was priced at $0.40 per share ...
(Date:2/16/2017)... N.J. , Feb. 16, 2017  Champions Oncology, ... in the development and sale of advanced technology solutions ... oncology drugs, today announced the addition of new cohorts ... These new models will expand Champions, product line ... head and neck cancer, AML, and non-small cell lung ...
Breaking Biology Technology:
(Date:2/8/2017)... 2017 The biometrics market has reached ... of organizations, desires to better authenticate or identify ... and challenge questions), biometrics is quickly working its ... market is driven by use cases, though there ... enterprise uses cases, with consumer-facing use cases encompassing ...
(Date:2/6/2017)... , Feb. 6, 2017 According to ... are driving border authorities to continue to embrace ... there are 2143 Automated Border Control (ABC) eGates ... deployed at more than 163 ports of entry ... to 2016 achieving a combined CAGR of 37%. ...
(Date:2/2/2017)... 1, 2017  Central to its deep commitment ... worldwide, The Japan Prize Foundation today announced the ... pushed the envelope in their respective fields of ... scientists are being recognized with the 2017 Japan ... only contribute to the advancement of science and ...
Breaking Biology News(10 mins):